Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

and Keveyis for the treatment of Primary Periodic Paralysis. The three products were the catalyst behind Xeris Biopharma’s delivery of strong full-year 2024 results, characterized by a record ...

and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for ...

and Keveyis for the treatment of Primary Periodic Paralysis. The three products were the catalyst behind Xeris Biopharma’s delivery of strong full-year 2024 results, characterized by a record ...

Discover the signs of Lyme disease that everyone must recognize, from the classic bull's-eye rash to neurological symptoms ...

If you worry about tying up money you may need, consider building a CD ladder to get periodic access to portions ... play a role to avoid rate-watching paralysis. Keep an eye on overall market ...

and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, ...